Three Major Advantages
of Seeking Medical
Treatment in China:

Peking Union Medical College Hospital (PUMCH) is a top-tier comprehensive hospital in China, with a history dating back over a century. It integrates medical treatment, teaching, and scientific research, and is renowned for its expertise in tackling complex and difficult diseases. PUMCH houses a large team of senior medical experts and advanced medical equipment, providing high-quality healthcare services to both domestic and international patients. It also plays a leading role in medical education and clinical research, contributing significantly to the development of China’s medical industry.

Shenzhen Third People's Hospital (a Class A tertiary research hospital administered by the Shenzhen Municipal People's Government and a designated Shenzhen Medical Insurance hospital) is located at 29 Bujibulan Road, Longgang District, Shenzhen. The current president is Lu Hongzhou. In 1985, Shenzhen Third People's Hospital's predecessor, Shenzhen Donghu Hospital, opened. In 1996, the Shenzhen Institute of Liver Diseases was established. In 2000, the hospital's renovation and expansion project was approved. In February 2003, it became the designated hospital for the treatment of SARS in Shenzhen. In January 2004, it was renamed "Shenzhen Third People's Hospital" and relocated to 29 Bulan Road, Longgang District. In 2008, the hospital was designated the Shenzhen Branch Laboratory of the State Key Laboratory of Emerging Infectious Diseases of the University of Hong Kong.

Guangdong Provincial People's Hospital is a large, modern, Class-A tertiary comprehensive hospital integrating medical care, teaching, and research. Its medical services are based in South China and radiate throughout the country, with key medical indicators ranking among the best in the country. It currently has 13 national key clinical specialties and 32 Guangdong Provincial key clinical medicine specialties, specializing in the multidisciplinary diagnosis and treatment of difficult and critical illnesses. In the five years ending in 2023, it has introduced 326 new medical technologies, completed the registration of 9 national and 62 provincial restricted clinical application technologies, including artificial intelligence-assisted treatment technology, and completed 35.78% of Level 4 surgeries. It currently has six outpatient clinics, six research institutes, six medical centers, and the Guangdong Bone Marrow Bank, among other clinical, teaching, and research institutions.